Omeros (OMER) Return on Capital Employed (2011 - 2026)
Omeros recorded quarterly Return on Capital Employed of 42.7% in Q1 2026, up 38.23% quarter-over-quarter from 69.14% in Q4 2025, and up 5151.0% year-over-year from 0.81% in Q1 2025.
Omeros' Return on Capital Employed history runs 16 years deep, the most recent figure standing at 42.7% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 5151.0% year-over-year to 42.7%; the TTM figure through Mar 2026 stood at 42.7% (up 5151.0% YoY), while the FY2025 annual figure was 54.99%, up 1229.0% from the prior year.
- Return on Capital Employed came in at 42.7% for Q1 2026 at Omeros, up from 69.14% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 37.6% in Q1 2023 to a low of 113.07% in Q3 2025.
- A 5-year average of 59.69% and a median of 48.12% in 2024 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed soared 13376 bps in 2022 and tumbled 5098 bps in 2025, its largest moves.
- Omeros' Return on Capital Employed stood at 42.12% in 2022, then declined by 2 bps to 43.03% in 2023, then sank by 80 bps to 77.41% in 2024, then rose by 11 bps to 69.14% in 2025, then soared by 38 bps to 42.7% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 42.7%, 69.14%, and 113.07% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Omeros | 772.03 Mn | 636.71 Mn | 9.31 Mn | -42.70% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -42.70% |
| Dec 31, 2025 | -69.14% |
| Sep 30, 2025 | -113.07% |
| Jun 30, 2025 | -102.81% |
| Mar 31, 2025 | -94.21% |
| Dec 31, 2024 | -77.41% |
| Sep 30, 2024 | -62.09% |
| Jun 30, 2024 | -55.16% |
| Mar 31, 2024 | -48.12% |
| Dec 31, 2023 | -43.03% |
| Sep 30, 2023 | -45.42% |
| Jun 30, 2023 | -41.85% |
| Mar 31, 2023 | -37.60% |
| Dec 31, 2022 | -42.12% |
| Sep 30, 2022 | -45.88% |
| Jun 30, 2022 | -48.66% |
| Mar 31, 2022 | -45.48% |
| Dec 31, 2021 | -79.07% |
| Sep 30, 2021 | -179.65% |
| Jun 30, 2021 | -142.02% |
| Mar 31, 2021 | -103.45% |
| Dec 31, 2020 | -66.10% |
| Sep 30, 2020 | -99.33% |
| Jun 30, 2020 | -152.76% |
| Mar 31, 2020 | -97.36% |
| Dec 31, 2019 | -108.06% |
| Sep 30, 2019 | -132.89% |
| Jun 30, 2019 | -150.45% |
| Mar 31, 2019 | -191.86% |
| Dec 31, 2018 | -231.78% |
| Sep 30, 2018 | -162.47% |
| Jun 30, 2018 | -105.85% |
| Mar 31, 2018 | -75.41% |
| Dec 31, 2017 | -46.39% |
| Sep 30, 2017 | -61.00% |
| Jun 30, 2017 | -140.24% |
| Mar 31, 2017 | -103.66% |
| Dec 31, 2016 | -100.61% |
| Sep 30, 2016 | -139.38% |
| Jun 30, 2016 | -271.16% |
| Mar 31, 2016 | -291.48% |
| Dec 31, 2015 | -246.05% |
| Sep 30, 2015 | -263.65% |
| Jun 30, 2015 | -152.11% |
| Mar 31, 2015 | -316.84% |
| Dec 31, 2014 | 27,891.63% |
| Sep 30, 2014 | -341.05% |
| Jun 30, 2014 | -165.67% |
| Mar 31, 2014 | -215.51% |
| Dec 31, 2013 | -2,103.52% |
| Sep 30, 2013 | -783.30% |
| Jun 30, 2013 | -461.71% |
| Mar 31, 2013 | -336.25% |
| Dec 31, 2012 | -173.10% |
| Sep 30, 2012 | 9,861.38% |
| Jun 30, 2012 | 1,934.01% |
| Mar 31, 2012 | -548.45% |
| Dec 31, 2011 | -228.45% |
| Sep 30, 2011 | -117.92% |